By Josh White
Date: Friday 14 Nov 2025
(Sharecast News) - Aptamer Group said on Friday that two new pharmaceutical contracts worth £0.19m had lifted its binding 2026 order book to £1.95m, marking continued commercial momentum and strengthening validation of its Optimer synthetic-binder platform among major global drugmakers.
By Josh White
Date: Tuesday 04 Nov 2025
(Sharecast News) - Aptamer Group announced on Tuesday that it has signed a new contract worth up to £0.62m with a top five global pharmaceutical company, marking the third collaboration between the two and further validating its 'Optimer' synthetic binder technology.
By Benjamin Chiou
Date: Monday 13 Oct 2025
(Sharecast News) - Life sciences group Aptamer on Monday announced a new fee-for-service development contract with an unnamed top 10 global pharma company.
| Currency | UK Pounds |
| Share Price | 0.90p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 1.30p |
| 52 Week Low | 0.25p |
| Volume | 2,084,858 |
| Shares Issued | 2,696.98m |
| Market Cap | £24.27m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 15:54 | 57,741 @ 0.87p |
| 15:02 | 10,514 @ 0.89p |
| 13:08 | 78,300 @ 0.89p |
| 12:52 | 12,976 @ 0.89p |
| 10:59 | 14,000 @ 0.89p |
| CEO | Arron Tolley |
| CFO | Andrew Rapson |
You are here: research